Hypoallergens for allergen-specific immunotherapy by directed molecular evolution of mite group 2 allergens.

Allergen-specific immunotherapy is the only treatment that provides long lasting relief of allergic symptoms. Currently, it is based on repeated administration of allergen extracts. To improve the safety and efficacy of allergen extract-based immunotherapy, application of hypoallergens, i.e. modified allergens with reduced IgE binding capacity but retained T-cell reactivity, has been proposed. It may, however, be difficult to predict how to modify an allergen to create a hypoallergen. Directed molecular evolution by DNA shuffling and screening provides a means by which to evolve proteins having novel or improved functional properties without knowledge of structure-function relationships of the target molecules. With the aim to generate hypoallergens we applied multigene DNA shuffling on three group 2 dust mite allergen genes, two isoforms of Lep d 2 and Gly d 2. DNA shuffling yielded a library of genes from which encoded shuffled allergens were expressed and screened. A positive selection was made for full-length, high-expressing clones, and screening for low binding to IgE from mite allergic patients was performed using an IgE bead-based binding assay. Nine selected shuffled allergens revealed 80-fold reduced to completely abolished IgE binding compared with the parental allergens in IgE binding competition experiments. Two hypoallergen candidates stimulated allergen-specific T-cell proliferation and cytokine production at comparable levels as the wild-type allergens in patient peripheral blood mononuclear cell cultures. The two candidates also induced blocking Lep d 2-specific IgG antibodies in immunized mice. We conclude that directed molecular evolution is a powerful approach to generate hypoallergens for potential use in allergen-specific immunotherapy.

The expression of lactate dehydrogenase is important for the cell cycle of Toxoplasma gondii.

In Toxoplasma gondii, lactate dehydrogenase is encoded by two independent and developmentally regulated genes LDH1 and LDH2. These genes and their products have been implicated in the control of a metabolic flux during parasite differentiation. To investigate the significance of LDH1 and LDH2 in this process, we generated stable transgenic parasite lines in which the expression of these two expressed isoforms of lactate dehydrogenase was knocked down in a stage-specific manner. These LDH knockdown parasites exhibited variable growth rates in either the tachyzoite or the bradyzoite stage, as compared with the parental parasites. Their differentiation processes were impaired when the parasites were grown under in vitro conditions. In vivo studies in a murine model system revealed that tachyzoites of these parasite lines were unable to form significant numbers of tissue cysts and to establish a chronic infection. Most importantly, all mice that were initially infected with tachyzoites of either of the four LDH knockdown lines survived a subsequent challenge with tachyzoites of the parental parasites (10(4)), a dose that usually causes 100% mortality, suggesting that live vaccination of mice with the LDH knockdown tachyzoites can confer protection against T. gondii. Thus, we conclude that LDH expression is essential for parasite differentiation. The knockdown of LDH1 and LDH2 expression gave rise to virulence-attenuated parasites that were unable to exhibit a significant brain cyst burden in a murine model of chronic infection.

Serotyping of Toxoplasma gondii infections in humans using synthetic peptides.

To determine whether the characteristics of disease due to Toxoplasma gondii (toxoplasmosis) are dependent on the infecting strain, we have developed an enzyme-linked immunosorbent assay for typing strains that uses infection serum reacted against polymorphic peptides derived from Toxoplasma antigens SAG2A, GRA3, GRA6, and GRA7. Pilot studies with infected mice established the validity of the approach, which was then tested with human serum. In 8 patients who had Sabin-Feldman dye test titers >64 and for whom the infecting strain type was known, the peptides correctly distinguished type II from non-type II infections. ELISA analysis of a second group of 10 infected pregnant women from whom the parasite strain had not been isolated gave a clear prediction of the strain type causing infection. This method should allow statistically significant data to be obtained about whether different strain types cause disease with different characteristics.

Evidence for nuclear localisation of two stage-specific isoenzymes of enolase in Toxoplasma gondii correlates with active parasite replication.

The protozoan parasite Toxoplasma gondii has a complex life cycle involving the developmental transition between the asexual exo-enteric stages (tachyzoites and bradyzoites) and the coccidian (sexual and asexual) forms (schizonts, macrogametes and microgametes). Previous work has established the stage-specific expression of certain proteins including two glycolytic isoenzymes of enolase and lactate dehydrogenase in T. gondii. Here we describe the expression and subcellular localisation of the two isoforms of enolase (ENO1 and ENO2) and lactate dehydrogenase (LDH1 and LDH2) in vivo using immunocytochemistry. In mice, proliferating parasites in the lung expressed ENO2 and LDH1 and were characterised as tachyzoites by the presence of a tachyzoite specific surface antigen (SAG1). In contrast, ENO1 and LDH2 were expressed by bradyzoites present in tissue cysts in the brain characterised by the presence of the bradyzoite specific antigen (BAG1). During stage conversion (tachyzoite/bradyzoite), the isoenzyme changes occur at an early stage when the bradyzoites are actively proliferating and thus may not simply be reflecting reduced metabolic needs. When the coccidian stages were examined in the cat intestine, they were negative for SAG1, BAG1, LDH2 and ENO1 but were similar to the tachyzoite in strongly expressing LDH1 and ENO2. The isoenzymes LDH1 and LDH2 were exclusively expressed in the cytoplasm. In contrast, it was observed that the strongest labelling for both ENO1 and ENO2 was observed in the nucleus with less intense but specific cytoplasmic staining. Immunoelectron microscopy confirmed the cytoplasmic location of LDH and the predominantly nuclear location of enolase. During early intracellular proliferation and development, all stages of the life cycle (tachyzoite, bradyzoite and coccidian stages) exhibited very strong nuclear labelling for enolase but this was markedly reduced in mature parasites to levels below that seen in the cytoplasm. The specific nuclear localisation of enolases appears to be associated with nuclear activity (transcription and/or division) and may play some part in the control of gene regulation during parasite proliferation and differentiation in addition to its role in glycolysis.

Protective effects of immunization with a recombinant cyst antigen in mouse models of infection with Toxoplasma gondii tissue cysts.

A portion of the major Toxoplasma gondii tissue cyst antigen (MAG1) was expressed in bacteria as a fusion to glutathione S-transferase (GST) and the purified fusion protein (rMAG1) was used to immunize mice in an attempt to induce protective immunity against challenge with live cysts from the T. gondii ME49 strain. Sixty percent of mice immunized with rMAG1 and challenged with 500 cysts of the T. gondii ME49 strain survived, while only 20% of mice immunized with GST alone survived, suggesting a protective effect specific to the MAG1 portion of the recombinant protein. In a model of chronic infection with ME49 cysts, rMAG1-immunized mice had significantly fewer cerebral cysts and reduced inflammation in the brain compared with mice immunized with GST alone.